PA
Pacific Biosciences of California, Inc.
PACB · NASDAQ
$1.30 +0.78% (+$0.01)
1M +13.04%
Market Cap $394.5M
P/E Ratio -
Div. Yield -
ROE -
Bulios Fair Price
$1.54
18.5% upside
Trenutna cena
$1.3
Podcenjeno Poštena vrednost Precenjeno
Po podatkih Bulios Fair Price je delnica PACB trenutno podcenjena glede na svojo tržno ceno. Kako deluje?
Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?
Piotroski F-Score Weak
2/9Valuation
67 /100
Cheap P/S 2.48x
P/E N/A
EV/EBITDA N/A
Growth
44 /100
Stable Rev. growth 7.64%
Book val. growth 78.82%
EPS growth N/A
Profitability
14 /100
Weak Gross margin 35.97%
Net margin 82.49%
Op. margin 102.05%
Quality
4 /100
Poor ROIC 23.90%
ROA 17.48%
Asset turnover 0.21x
Debt
43 /100
Moderate Current ratio 4.92x
Int. coverage -32.92x
Debt/Equity N/A
Stability
14 /100
Unstable Beta 2.31x
Rev. volatility 40.41%
EPS volatility 47.74%
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
Vprašajte StockBota o PACB
Online
Sector
Healthcare
Industry
Medical - Devices
CEO
Mark Van Oene
Employees
485
Headquarters
Menlo Park
Prihajajoči dogodki
03 NOV.
Earnings
Upcoming earnings report
09 FEB.
Earnings
Upcoming earnings report